Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis

“…We observed very similar response rates in our preliminary report in 2006; six out of nine patients with acute severe UC (Truelove and Witts criteria) responded and avoided colectomy with relatively few adverse events 25 . A Cochrane meta‐analysis has concluded that in patients who do not respond to a combination of cortico‐steroids and immunomodulators, infliximab is better than placebo for the induction of remission 26 . It is also stated that although adverse events are relatively infrequent ‘…physicians should be aware of and be prepared to deal with potential adverse events such as anaphylactic reactions and infections’.…”

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis

“…We observed very similar response rates in our preliminary report in 2006; six out of nine patients with acute severe UC (Truelove and Witts criteria) responded and avoided colectomy with relatively few adverse events 25 . A Cochrane meta‐analysis has concluded that in patients who do not respond to a combination of cortico‐steroids and immunomodulators, infliximab is better than placebo for the induction of remission 26 . It is also stated that although adverse events are relatively infrequent ‘…physicians should be aware of and be prepared to deal with potential adverse events such as anaphylactic reactions and infections’.…”

Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis

“…Indeed, Probert et al found no statistically significant difference between the two treatment arms in terms of clinical remission or quality of life (measured using the Inflammatory Bowel Disease Questionnaire and the EuroQol scale). Differences in endoscopic remission rates did not achieve statistical significance either, with a RR of 0.87 and a 95% CI of 0.33 to 2.27 (8).…”

Anti-inflammatory effect of a standardized triterpenoid-rich fraction isolated from Rubus coreanus on dextran sodium sulfate-induced acute colitis in mice and LPS-induced macrophages

“…Elevated pro-inflammatory cytokine levels are observed in the inflamed gut of IBD patients and in animals with DSS-induced colitis (Pullman et al, 1992;Dieleman et al, 1998). In addition, it has been reported in previous studies that anti-cytokine antibodies (anti-TNF or anti-IL-1β) and cytokine receptor antagonists ameliorate colitis progression clinically and in animal models of experimental colitis (Tountas et al, 1999;Kwon et al, 2005;Lawson et al, 2006;Levin and Shibolet, 2008). In this study, it was observed that the levels of proinflammatory cytokines, such as, TNF-α, IL-1β, and IL-6, were elevated in the colonic tissues of DSS only-treated group, and that the administration of TFRC to DSS-treated mice markedly reduced the production and expression of TNF-α, IL-1β, and IL-6.…”

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis

“…We observed very similar response rates in our preliminary report in 2006; six out of nine patients with acute severe UC (Truelove and Witts criteria) responded and avoided colectomy with relatively few adverse events 25 . A Cochrane meta‐analysis has concluded that in patients who do not respond to a combination of cortico‐steroids and immunomodulators, infliximab is better than placebo for the induction of remission 26 . It is also stated that although adverse events are relatively infrequent ‘…physicians should be aware of and be prepared to deal with potential adverse events such as anaphylactic reactions and infections’.…”

Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis

“…Indeed, Probert et al found no statistically significant difference between the two treatment arms in terms of clinical remission or quality of life (measured using the Inflammatory Bowel Disease Questionnaire and the EuroQol scale). Differences in endoscopic remission rates did not achieve statistical significance either, with a RR of 0.87 and a 95% CI of 0.33 to 2.27 (8).…”

Anti-inflammatory effect of a standardized triterpenoid-rich fraction isolated from Rubus coreanus on dextran sodium sulfate-induced acute colitis in mice and LPS-induced macrophages

“…Elevated pro-inflammatory cytokine levels are observed in the inflamed gut of IBD patients and in animals with DSS-induced colitis (Pullman et al, 1992;Dieleman et al, 1998). In addition, it has been reported in previous studies that anti-cytokine antibodies (anti-TNF or anti-IL-1β) and cytokine receptor antagonists ameliorate colitis progression clinically and in animal models of experimental colitis (Tountas et al, 1999;Kwon et al, 2005;Lawson et al, 2006;Levin and Shibolet, 2008). In this study, it was observed that the levels of proinflammatory cytokines, such as, TNF-α, IL-1β, and IL-6, were elevated in the colonic tissues of DSS only-treated group, and that the administration of TFRC to DSS-treated mice markedly reduced the production and expression of TNF-α, IL-1β, and IL-6.…”

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis

“…We observed very similar response rates in our preliminary report in 2006; six out of nine patients with acute severe UC (Truelove and Witts criteria) responded and avoided colectomy with relatively few adverse events 25 . A Cochrane meta‐analysis has concluded that in patients who do not respond to a combination of cortico‐steroids and immunomodulators, infliximab is better than placebo for the induction of remission 26 . It is also stated that although adverse events are relatively infrequent ‘…physicians should be aware of and be prepared to deal with potential adverse events such as anaphylactic reactions and infections’.…”

Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis

“…Indeed, Probert et al found no statistically significant difference between the two treatment arms in terms of clinical remission or quality of life (measured using the Inflammatory Bowel Disease Questionnaire and the EuroQol scale). Differences in endoscopic remission rates did not achieve statistical significance either, with a RR of 0.87 and a 95% CI of 0.33 to 2.27 (8).…”

Anti-inflammatory effect of a standardized triterpenoid-rich fraction isolated from Rubus coreanus on dextran sodium sulfate-induced acute colitis in mice and LPS-induced macrophages

“…Elevated pro-inflammatory cytokine levels are observed in the inflamed gut of IBD patients and in animals with DSS-induced colitis (Pullman et al, 1992;Dieleman et al, 1998). In addition, it has been reported in previous studies that anti-cytokine antibodies (anti-TNF or anti-IL-1β) and cytokine receptor antagonists ameliorate colitis progression clinically and in animal models of experimental colitis (Tountas et al, 1999;Kwon et al, 2005;Lawson et al, 2006;Levin and Shibolet, 2008). In this study, it was observed that the levels of proinflammatory cytokines, such as, TNF-α, IL-1β, and IL-6, were elevated in the colonic tissues of DSS only-treated group, and that the administration of TFRC to DSS-treated mice markedly reduced the production and expression of TNF-α, IL-1β, and IL-6.…”